期刊文献+

植物营养成分对慢性疾病的影响评估——转基因技术面临的挑战 被引量:1

Evaluation on Influence of Plant Nutrients on Chronic Diseases——Challenges Facing Transgenic Technology
下载PDF
导出
摘要 减少慢性疾病是二十一世纪社会面临的最紧迫的挑战。本文回顾了植物性营养成分可以防止或减少主要慢性疾病发生风险的一些证据和作用机制,尤其是在识别和理解食品对健康的促进成分,转基因技术是解决这一重大问题的重要植物育种工具。同时倡导科学地研究植物,确保膳食推荐的合理性和准确性,以减少慢性疾病所带来的经济负担。转基因技术应用于农业和食品工业,产生了转基因食品。为了更好地造福人类,我国制订的法规和条例为转基因生物提供了安全性和营养性的有力保障;相应的转基因食品检测方法是转基因的安全评价及监督监管的技术保障。近年来,出现了有关去除选择性标记基因的新策略,本文也介绍了去除选择性标记基因的未来研究方向和植物科学的未来需要,因此,对促进人们接受转基因农作物将起到积极因素。 Control of chronic diseases is the most urgent challenge facing the world community in the 21st century. Firstly, this paper reviews some evidences and action mechanisms underlying the capability of plant nutrients in risk control of chronic diseases, contending that transgenic technology is an important breeding tool to solve this serious problem, especially in identifying and understanding the health -promoting components in foods. Secondly, the paper advocates closer study of plants to ensure rational and accu- rate diets to minimize economic costs caused by chronic diseases. Genetically modified foods (GMF) are produced when transgenic technology is applied to farming and the food industry. To benefit human beings, laws and administrative regulations have been formulated by the Chinese government to safeguard both safety and nutrition of foods and, correspondingly, inspection methods for GMFs have been adopted as technical guarantee of both their safety evaluation and supervision. In recent years, a new strategy is emerging involving the removal of marker genes. To this new tendency this papers devotes some space to describing its future direction as well as the need for plant science, hoping to make genetically modified crops more acceptable to the public.
作者 阎力君 田硕
出处 《楚雄师范学院学报》 2014年第8期6-14,共9页 Journal of Chuxiong Normal University
关键词 慢性疾病 植物性营养成分 转基因技术 转基因食品安全性 去除标记基因 chronic disease, plant nutrient, transgenic technology, safety of genetically modified food (GMF) , removal of marker gene
  • 相关文献

参考文献2

二级参考文献38

  • 1Kuwayama H. Zinc compound is a novel, highly effective triple therapy for eradication of Helicobacter pylori. Gastroenterology 1995; 108: A138.
  • 2Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E. Effect of genetic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69: 158-168 .
  • 3Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, Nasu J, Okada H, Yokota K, Oguma K, Tsuji T. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol 2001; 16: 723-728.
  • 4Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-meohenyton 4'-hydroxylation status. Clin Pharmacol Ther 1995; 58: 143-154.
  • 5Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis 1990; 161: 626-633.
  • 6Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989; 96: 615-625.
  • 7Graham DY, Lew GM, Evans DG, Evans DJ, Klein PD. Effect of triple therapy (antibiotic plus bismuth) on duodenal ulcer healing. Ann Int Med 1991; 115: 266-269.
  • 8Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-1252.
  • 9Tytgat GN. Review article: treatments that impact favorably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359-368.
  • 10Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. European Helicobacter pylori study group (EHPSG). Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002; 16: 167-180.

共引文献8

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部